About Cour Pharma
Cour Pharma is a company based in Chicago (United States) founded in 2013. Cour Pharma has raised $135.2 million across 6 funding rounds from investors including Pfizer, Roche and Bristol-Myers Squibb. The company has 31 employees as of December 31, 2021. Cour Pharma offers products and services including CNP-103 and CNP-106. Cour Pharma operates in a competitive market with competitors including Moderna, BeiGene, Biogen, Incyte and ADMA Biologics, among others.
- Headquarter Chicago, United States
- Employees 31 as on 31 Dec, 2021
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$135.2 M (USD)
in 6 rounds
-
Latest Funding Round
$105 M (USD), Series A
Jan 30, 2024
-
Investors
Pfizer
& 6 more
-
Employee Count
31
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cour Pharma
Cour Pharma offers a comprehensive portfolio of products and services, including CNP-103 and CNP-106.
Therapy to induce tolerance for type 1 diabetes using nanoparticles
Treatment for myasthenia gravis via immune-modifying nanoparticles
People of Cour Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Cour Pharma
Cour Pharma has successfully raised a total of $135.2M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $105 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cour Pharma
Cour Pharma has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Roche and Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Lumira Ventures is engaged in life sciences venture capital investment.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on growth-stage companies
|
Locked | Locked | Locked | |
|
Angelini Ventures is focused on investing in BioTech and Digital Health.
|
Locked | Locked | Locked |
Investor details for Cour Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cour Pharma
Investment portfolio details for Cour Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cour Pharma
Detailed financials for Cour Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cour Pharma Comparisons
Peer comparison for Cour Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cour Pharma
Cour Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Biogen, Incyte and ADMA Biologics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies for cancer and other diseases are developed.
|
Detailed competitors of Cour Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cour Pharma
Complete news archive for Cour Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cour Pharma
Cour Pharma was founded in 2013.
Cour Pharma is headquartered in Chicago, United States. It is registered at Chicago, Illinois, United States.
Cour Pharma is a funded company, having raised a total of $135.2M across 6 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Cour Pharma is 31.
Cour Pharma was founded in 2013 and is based in Chicago, United States. Operations focus on the biotechnology sector, where proprietary nanoparticle platforms are utilized for immune-related conditions. Immune Modifying Nanoparticles target severe inflammations by binding to monocytes for elimination, while Tolerizing Immune Modifying Nanoparticles introduce antigens to reprogram the immune system against autoimmune and allergic disorders. The nanoparticles consist of an FDA-approved biodegradable copolymer.
Cour Pharma's top competitors include Moderna, BeiGene and ADMA Biologics.
Cour Pharma offers CNP-103 and CNP-106.
Cour Pharma has 7 investors. Key investors include Pfizer, Roche, Bristol-Myers Squibb, Lumira Ventures, and Alpha Wave Global.